Current Liabilities decreased faster than Neurometrix Inc 's Cash & cash equivalent, this led to improvement in Neurometrix Inc 's Quick Ratio to 14.47, above Neurometrix Inc average Quick Ratio.

Within Medical Equipment & Supplies industry 8 other companies have achieved higher Quick Ratio than Neurometrix Inc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 176 to 364.

Explain Quick Ratio?
How much Cash & cash equivalents NURO�s has?
What are NURO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NURO Quick Ratio	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	-27.04 %	-15.32 %	31.4 %	30.36 %	12.13 %
Y / Y Cash & cash equivalent Change	-27.24 %	-15.89 %	-11.82 %	-49.23 %	-15.11 %
Quick Ratio MRQ	14.47	13.9	10.33	9.53	14.51
NURO's Total Ranking	# 364	# 176	# 184	# 216	# 113
Seq. Current Liabilities Change	-15.19 %	-32.87 %	-13.93 %	48.9 %	-1.57 %
Seq. Cash & cash equivalent Change	-11.73 %	-9.71 %	-6.64 %	-2.21 %	2.04 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 9
Healthcare Sector	# 91
Overall Market	# 364

Quick Ratio Statistics
High	Average	Low
24.46	6.16	0.81
(Mar 31 2023)		(Sep 30 2019)

Financial Statements
Neurometrix Inc 's Current Liabilities	$ 1 Millions	Visit NURO's Balance sheet
Neurometrix Inc 's Cash & cash equivalent	$ 13 Millions	Visit NURO's Balance sheet
Source of NURO's Sales		Visit NURO's Sales by Geography

Cumulative Neurometrix Inc 's Quick Ratio

NURO's Quick Ratio for the trailling 12 Months

NURO Quick Ratio	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	5.49 %	15.04 %	6.69 %	-6.48 %	-18 %
Y / Y Cash & cash equivalent TTM Growth	-30.33 %	-27.43 %	-26.92 %	-27.89 %	0.19 %
Quick Ratio TTM	11.45	11.64	11.73	12.93	17.34
Total Ranking TTM	# 3379	# 2810	# 2783	# 2728	# 2906
Seq. Current Liabilities TTM Growth	-5.84 %	-3.25 %	6.84 %	8.39 %	2.69 %
Seq. Cash & cash equivalent TTM Growth	-7.33 %	-4.02 %	-3.06 %	-19.19 %	-3.48 %

Quick ratio ranking by company, industry and sector >> Back to NURO Financial Strength Comparisons >> Go to Compare NURO Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in NURO's Current Liabilities to $0.91 millions, cumulative Quick Ratio to 11.45 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 189 other companies have achieved higher Quick Ratio than Neurometrix Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 2810 to 3379.

Explain Quick Ratio?
How much Cash & cash equivalents NURO�s has?
What are NURO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 190
Healthcare Sector	# 925
Within the Market	# 3379

trailing twelve months Quick Ratio Statistics
High	Average	Low
14.42	5.4	0.93
(Jun 30 2022)		(Mar 31 2020)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Medical Equipment & Supplies Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
EBR Systems, Inc.	34.85	$ 131.177 Millions	$ 3.764 Millions
Vivos Inc	25.66	$ 2.213 Millions	$ 0.086 Millions
Utah Medical Products Inc	22.09	$ 82.976 Millions	$ 3.757 Millions
Envveno Medical Corporation	20.60	$ 43.153 Millions	$ 2.095 Millions
Soleno Therapeutics Inc	17.78	$ 291.437 Millions	$ 16.395 Millions
Beta Bionics Inc	17.33	$ 103.575 Millions	$ 5.977 Millions
Ceribell Inc	16.47	$ 194.370 Millions	$ 11.804 Millions
Perspective Therapeutics Inc	14.77	$ 276.973 Millions	$ 18.756 Millions
Neurometrix Inc	14.47	$ 13.095 Millions	$ 0.905 Millions
Strata Critical Medical Inc	13.93	$ 128.404 Millions	$ 9.220 Millions
Pulse Biosciences Inc	11.74	$ 118.038 Millions	$ 10.055 Millions
Autonomix Medical Inc	11.08	$ 8.608 Millions	$ 0.777 Millions
Alpha Tau Medical Ltd	10.23	$ 62.855 Millions	$ 6.146 Millions
Monogram technologies inc	10.16	$ 15.658 Millions	$ 1.541 Millions
Cvrx inc	9.84	$ 105.933 Millions	$ 10.762 Millions
Lemaitre Vascular Inc	9.79	$ 299.722 Millions	$ 30.607 Millions
Inspire Medical Systems inc	9.17	$ 811.937 Millions	$ 88.501 Millions
Rxsight Inc	9.17	$ 237.223 Millions	$ 25.876 Millions
Vicarious Surgical Inc	9.12	$ 58.834 Millions	$ 6.449 Millions
Bone Biologics Corporation	8.91	$ 3.325 Millions	$ 0.373 Millions
Delcath Systems Inc	8.81	$ 53.233 Millions	$ 6.039 Millions
Modular Medical Inc	8.53	$ 9.232 Millions	$ 1.082 Millions
Inmode Ltd	8.44	$ 596.913 Millions	$ 70.754 Millions
Profound Medical Corp	8.36	$ 54.912 Millions	$ 6.565 Millions
Collplant Biotechnologies Ltd	7.97	$ 12.157 Millions	$ 1.526 Millions
Sight Sciences Inc	7.78	$ 120.357 Millions	$ 15.468 Millions
Orasure Technologies Inc	7.62	$ 267.763 Millions	$ 35.155 Millions
Valion Bio Inc	7.36	$ 2.002 Millions	$ 0.272 Millions
Carlsmed Inc	7.30	$ 40.125 Millions	$ 5.499 Millions
Penumbra Inc	7.09	$ 340.131 Millions	$ 47.949 Millions

Date modified: 2026-09-26T09:59:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.